Maria Grazia D’Errigo

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

R. Latagliata, C. Finelli, F. Morabito, 2013, Leukemia & lymphoma.

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

A. Stamatoullas, M. Voso, R. Latagliata, 2017, The Lancet. Haematology.

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

M. Voso, R. Latagliata, P. Fenaux, 2019, Blood.

Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence

R. Latagliata, U. Germing, A. Cortelezzi, 2015, Cancer medicine.

Changes in RPS14 expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletion

R. Latagliata, C. Finelli, F. Morabito, 2010, European journal of haematology.

Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.

R. Latagliata, E. Sabattini, F. Pane, 2021, American journal of blood research.